European Journal of Pharmaceutical Sciences,
Год журнала:
2024,
Номер
198, С. 106793 - 106793
Опубликована: Май 11, 2024
The
revolutionary
Proteolysis
Targeting
Chimera
(PROTACs)
have
the
exciting
potential
to
reshape
pharmaceutical
industry
landscape
by
leveraging
ubiquitin-proteasome
system
for
targeted
protein
degradation.
Breast
cancer,
most
prevalent
cancer
in
women,
could
be
treated
using
PROTAC
therapy.
Although
substantial
work
has
been
conducted,
there
isn't
yet
a
comprehensive
overview
or
progress
update
on
therapy
breast
cancer.
Hence,
this
article,
we've
compiled
recent
research
focusing
different
target
proteins,
such
as
estrogen
receptor
(ER),
BET,
CDK,
HER2,
PARP,
EZH2,
etc.
This
resource
aims
serve
guide
future
PROTAC-based
treatment
design.
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Апрель 18, 2024
Triple-negative
breast
cancer
(TNBC)
poses
a
significant
clinical
challenge
due
to
its
propensity
for
metastasis
and
poor
prognosis.
TNBC
evades
the
body's
immune
system
recognition
attack
through
various
mechanisms,
including
Janus
Kinase
2
(JAK2)/signal
transducer
activator
of
transcription
3
(STAT3)
signaling
pathway.
This
pathway,
characterized
by
heightened
activity
in
numerous
solid
tumors,
exhibits
pronounced
activation
specific
subtypes.
Consequently,
targeting
JAK2/STAT3
pathway
emerges
as
promising
precise
therapeutic
strategy
TNBC.
The
signal
transduction
cascade
predominantly
involves
receptor
tyrosine
kinases,
kinase
JAK2,
factor
STAT3.
Ongoing
preclinical
studies
research
are
actively
investigating
this
potential
target
treatment.
article
comprehensively
reviews
investigations
into
treatment
using
small
molecule
compounds.
review
explores
role
therapeutics,
evaluating
benefits
limitations
active
inhibitors
proteolysis-targeting
chimeras
aim
is
facilitate
development
novel
small-molecule
compounds
that
effectively.
Ultimately,
work
seeks
contribute
enhancing
efficacy
patients
with
International Journal of Pharmaceutics X,
Год журнала:
2024,
Номер
7, С. 100237 - 100237
Опубликована: Март 11, 2024
In
this
study,
we
present
a
targeted
and
pH-sensitive
niosomal
(pHSN)
formulation,
incorporating
quantum
dot
(QD)-labeled
Trastuzumab
(Trz)
molecules
for
the
specific
delivery
of
Palbociclib
(Pal)
to
cells
overexpressing
human
epidermal
growth
factor
receptor
2
(HER2).
FTIR
analyses
confirmed
successful
preparation
pHSNs
their
bioconjugation.
The
labeled
Trz-conjugated
Pal-pHSNs
(Trz-Pal-pHSNs)
exhibited
size
approximately
170
nm,
displaying
spherical
shape
with
neutral
surface
charge
−1.2
mV.
Pal
encapsulation
reached
~86%,
release
pattern
followed
two-phase
pH-dependent
mechanism.
MTT
assessments
demonstrated
enhanced
apoptosis
induction,
particularly
in
HER2-positive
cells,
by
Trz-Pal-pHSNs.
Fluorescence
imaging
further
validated
internalization
particles
into
cells.
conclusion,
Trz-Pal-pHSNs
emerge
as
promising
platform
personalized
medicine
treatment
breast
cancer.
European Journal of Pharmaceutical Sciences,
Год журнала:
2024,
Номер
198, С. 106793 - 106793
Опубликована: Май 11, 2024
The
revolutionary
Proteolysis
Targeting
Chimera
(PROTACs)
have
the
exciting
potential
to
reshape
pharmaceutical
industry
landscape
by
leveraging
ubiquitin-proteasome
system
for
targeted
protein
degradation.
Breast
cancer,
most
prevalent
cancer
in
women,
could
be
treated
using
PROTAC
therapy.
Although
substantial
work
has
been
conducted,
there
isn't
yet
a
comprehensive
overview
or
progress
update
on
therapy
breast
cancer.
Hence,
this
article,
we've
compiled
recent
research
focusing
different
target
proteins,
such
as
estrogen
receptor
(ER),
BET,
CDK,
HER2,
PARP,
EZH2,
etc.
This
resource
aims
serve
guide
future
PROTAC-based
treatment
design.
